Gotham Asset Management LLC cut its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 78.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,702 shares of the biotechnology company's stock after selling 24,539 shares during the quarter. Gotham Asset Management LLC's holdings in Repligen were worth $965,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD lifted its position in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares during the period. Groupama Asset Managment lifted its position in shares of Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company's stock valued at $58,142,000 after acquiring an additional 400,680 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Repligen during the 4th quarter valued at $53,428,000. Raymond James Financial Inc. acquired a new position in shares of Repligen during the 4th quarter valued at $52,492,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after acquiring an additional 203,011 shares during the period. 97.64% of the stock is owned by institutional investors.
Repligen Price Performance
Shares of RGEN stock traded down $2.30 during trading hours on Friday, reaching $118.15. The stock had a trading volume of 615,767 shares, compared to its average volume of 739,361. The stock's fifty day simple moving average is $130.28 and its 200 day simple moving average is $144.49. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The firm has a market capitalization of $6.64 billion, a PE ratio of -231.67, a PEG ratio of 4.54 and a beta of 1.21.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same period in the previous year, the firm earned $0.28 earnings per share. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on RGEN shares. Royal Bank of Canada dropped their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Canaccord Genuity Group lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective on the stock. Wall Street Zen upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Finally, Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a report on Tuesday, April 29th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $173.25.
Check Out Our Latest Analysis on RGEN
Insider Buying and Selling
In related news, Director Margaret Pax acquired 250 shares of Repligen stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by insiders.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
